Verici Dx commercializes RNA signatures based tests to decipher the body’s clinical messages to provide data driven insights to clinicians their patients. Currently we are validating a complementary suite of leading-edge tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes.
The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.
The Company also has a mission to accelerate the pace of innovation by research using the fully characterized data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners. We are singularly focused on providing insights that informs the path to overall graft survival and successful outcomes for patients.
Who we are
We believe in the diagnostic power of RNA signatures to bring substance to the promise of personalized medicine. We hold ourselves to the highest of standards and are proud to be supported by a strong foundation of core values. These values guide us and push us through the rigors of science and precision to deliver the data-driven answers clinicans and their patients deserve.
First revenues from Tutivia™ following full commercial launch Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, provides an update on its operational progress made since the release of its interim results in September 2022.Verici Dx continues to execute the commercial introduction of Tutivia™, the Company’s first product for kidney […]
